Fundraising Fox
Geneticure
Eden Prairie, US · Founded 2013 · Delaware corporation · 9 employees on LinkedIn · 2 known investors
Find your way into Geneticure
Sign up to see every warm intro you have to Geneticure
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Geneticure team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Geneticure offers a patented genetic test that uses a cheek-swab DNA sample, analyzing 17 genotypes across 11 genes to recommend personalized hypertension (blood pressure) treatment plans. The test helps doctors prescribe effective treatments by assessing the responsiveness of the patient's cardiac, vascular, and renal systems, reducing trial-and-error prescribing.
Founders & leadership
Geneticure was founded in 2013 by Scott Snyder.
SS
Scott SnyderFounder · CEOScott Snyder is CEO of Geneticure, a precision medicine company backed by Mayo Clinic that develops genetic testing to guide treatment selection for hypertension.
TO
Tom OlsonChief Clinical Officer
Investors · 2
Southeast Minnesota Capital Fundlisted by Southeast Minnesota Capital FundRochester
How we know: Southeast Minnesota Capital Fund's portfolio page · Not right? Tell us
Wireframe Ventureslisted by Wireframe VenturesSan Francisco · $500K – $2M
How we know: Wireframe Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 3 rounds · 2016–2017
▶$200KraisedApr 2017 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedApr 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott SnyderExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $200K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$250KraisedOct 2016 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedOct 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott SnyderExecutive Officer
- Offering amount
- $400K
- Amount sold
- $250K
- Minimum investment
- $50K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$665KraisedMay 2016 · 7 investors · Biotechnology
▶$665KraisedMay 2016 · 7 investors · Biotechnology
Officers, directors & promoters on the filing
- SCOTT SNYDERExecutive Officer
- BEN BOWMANExecutive Officer
- ERIC SYNDERExecutive Officer
- RYAN SPRISSLERExecutive Officer
- THOMAS OLSONExecutive Officer
- Offering amount
- $890K
- Amount sold
- $665K
- Minimum investment
- $25K
- First sale
- Mar 2016
- Incorporated
- Limited Liability Company, Minnesota, 2013
- Federal exemptions
- 04.1
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
GenomindGenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Self DecodeSelfDecode is a consumer genomics platform that analyzes users' DNA, blood test results, and lifestyle data to generate 1,500+ personalized health reports and AI-driven recommendations on diet, supplements, and lifestyle. It sells DNA test kits and subscription access to tools including an AI health assistant (DecodyGPT) and lab analysis, serving consumers, doctors, and businesses.
23andMe23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery. The company enables individuals to learn about their genetic traits while contributing to medical research studies that benefit public health.
Companies working in the same space as Geneticure.
Frequently asked questions
- What does Geneticure do?
- Geneticure offers a patented genetic test that uses a cheek-swab DNA sample, analyzing 17 genotypes across 11 genes to recommend personalized hypertension (blood pressure) treatment plans. The test helps doctors prescribe effective treatments by assessing the responsiveness of the patient's cardiac, vascular, and renal systems, reducing trial-and-error prescribing.
- Who founded Geneticure?
- Geneticure was founded by Scott Snyder in 2013.
- Who are Geneticure's investors?
- Geneticure's investors include Southeast Minnesota Capital Fund, Wireframe Ventures.
- How much funding has Geneticure raised?
- Geneticure has disclosed $1.1M raised across 3 rounds.
- Where is Geneticure headquartered?
- Geneticure is headquartered in Eden Prairie, US.